Through the lobbying arm PhRMA (Pharmaceutical Research and Manufacturers of America), manufacturers like Pfizer, Eli Lilly, Amgen, and AstraZeneca are seeking to erode confidence in Pharmacy Benefit Managers (PBMs) and actively work to fuel the legislative backlash occurring to remove their stranglehold on the pharmaceutical industry. Even with President Donald Trump’s executive order to lower prescription drug prices, actual federal legislation to rein in PBMs only nibbles around the edges of the problem, leaving the job to the states to battle this industry. A number of states across the country have already introduced restrictive bills and passed laws undercutting PBMs’ power, and other measures are in the works. Many state lawmakers lay the destruction of independent pharmacies at the feet of PBMs like CVS Caremark and UnitedHealthcare. Because of the drug prices set…
PhRMA Uses Advocacy Groups, Advertising to Turn PBMs Into the Villains in the War Over Drug Prices – RedState
